Evidence map›Paper›PMID 29374325›Full record

ReviewCurrent psychiatry reports2018

Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.

Shyam C Panchal, William G Ondo

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current psychiatry reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Clozapine augmentation strategies.The mental health clinician · 2019
    Article
  5. Review
  6. Treatment of Visual Disorders in Parkinson Disease.Current treatment options in neurology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Shyam C PanchalDepartment of Neurology, Houston Methodist Neurological Institute, 6560 Fannin Street; Scurlock Tower, Suite 802, Houston, TX, 77030, USA. spanchal@houstonmethodist.org.
William G OndoDepartment of Neurology, Houston Methodist Neurological Institute, 6560 Fannin Street; Scurlock Tower, Suite 802, Houston, TX, 77030, USA.
Houston Methodist · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewWe discuss features of Parkinson's disease psychosis (PDP) including symptomology and pathophysiology. Treatment options, including non-pharmacologic strategies, dose reduction of offending agents, and the addition of non-dopaminergic antipsychotics, are addressed. The efficacy of second-generation antipsychotics and novel agents is examined. RECENT

findingsPimavanserin, a 5-HT

Indexed as

Antipsychotic AgentsDelusionsHallucinationsHumansParkinson DiseasePiperidinesPsychotic DisordersSerotonin 5-HT2 Receptor AntagonistsUreaAntipsychotic AgentspimavanserinPiperidinesSerotonin 5-HT2 Receptor AntagonistsUreaAntipsychoticDelusionsHallucinationsParkinson’s diseasePimavanserinPsychosis

Identifiers

PMID29374325
OpenAlexW2792906834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.